GlassScriptPhysician profile
Amanda S Rowsey
NPI 1073104626
$4,520.03
in general payments reported to CMS, 2019-2025
26 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,073 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,520.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,199.59 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.90 | 2024-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $402.28 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $361.52 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $274.96 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $252.01 | 2024-2025 | Entyvio, Gattex |
| Novo Nordisk INC | $231.51 | 2024-2025 | Wegovy |
| Gilead Sciences, INC. | $170.17 | 2024 | Epclusa |
| Genzyme Corporation | $153.32 | 2024-2025 | |
| Qol Medical, LLC | $142.81 | 2024 | Sucraid |
| Madrigal Pharmaceuticals | $128.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $110.59 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Ironwood Pharmaceuticals, INC | $100.78 | 2024-2025 | |
| Celltrion USA INC. | $84.57 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $67.19 | 2024 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $59.05 | 2024 | Tremfya |
| Aimmune Therapeutics, INC. | $52.45 | 2024 | |
| Intercept Pharmaceuticals, INC. | $49.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $48.26 | 2024-2025 | Airsupra, Breztri |
| Shield Therapeutics INC | $44.24 | 2024 | |
| Pfizer INC. | $42.64 | 2024 | |
| Exact Sciences Corporation | $29.44 | 2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $28.35 | 2025 | Ohtuvayre |
| Pharmacosmos Therapeutics INC. | $18.71 | 2024 | Monoferric |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.65 | 2025 | Caplyta |
| Evoke Pharma, INC. | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rowsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.